Fasturtec 1.5 mg Powder and solvent for solution for infusion 1ml Vial 3pcs

For comprehensive product information and availability, please refer to leading e-commerce platforms like Nahdi Online, , or .

Product Overview

Benefits of Use

• Rapid Uric Acid Reduction: Fasturtec provides a swift and highly effective means to lower plasma uric acid levels, crucial during acute phases of hyperuricemia.
• Prevention of Acute Renal Failure: By facilitating the removal of uric acid, it significantly reduces the risk of uric acid crystallizing in the kidneys, thereby preventing acute renal injury and failure.
• Management of Tumor Lysis Syndrome (TLS): It is a cornerstone therapy in managing and preventing the severe metabolic abnormalities associated with TLS in patients undergoing chemotherapy for hematologic malignancies.
• Improved Patient Outcomes: Early intervention with Fasturtec can help improve overall patient prognosis and reduce the need for more invasive treatments like dialysis.

How to Use

1. Reconstitution: The powder in the vial is reconstituted with the provided solvent to form a clear solution.
2. Dilution: The reconstituted solution is then further diluted in an appropriate intravenous fluid (e.g., 0.9% sodium chloride).
3. Administration: The diluted solution is administered as an intravenous infusion over a specified period, typically 30 minutes.
4. Dosage: Dosage and duration of treatment are determined by the physician based on the patient's body weight, baseline uric acid levels, and clinical response.
5. Monitoring: During and after administration, patients will be closely monitored for uric acid levels, kidney function, and potential adverse reactions.

Caution & Warnings

• Hypersensitivity Reactions: Severe hypersensitivity reactions, including anaphylaxis, can occur. Patients should be closely monitored during and after infusion.
• G6PD Deficiency: Fasturtec is contraindicated in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia and methemoglobinemia. Screening for G6PD deficiency is recommended prior to treatment.
• Hemolysis and Methemoglobinemia: These serious adverse events can occur, particularly in patients with G6PD deficiency.
• Pregnancy and Lactation: Not recommended during pregnancy unless clearly necessary and the potential benefits outweigh the risks. Women of childbearing potential should use effective contraception during and for a period after treatment. Consult your doctor regarding use during lactation.
• Drug Interactions: Discuss all medications, including over-the-counter drugs and supplements, with your physician to avoid potential interactions.
• Storage: Store unopened vials in a refrigerator (2°C - 8°C) and protect from light. Do not freeze. Reconstituted and diluted solutions have specific stability guidelines and should be used promptly.

Ingredients

• Active Ingredient: Rasburicase 1.5 mg
• Inactive Ingredients: Mannitol, Disodium Phosphate Dodecahydrate, Disodium Phosphate Dihydrate, Tromethamine.

Product Details